ACPU
ALNY icon

Arrowgrass Capital Partners (US)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-50,000
Closed -$4.02M – 69
2019
Q3 		$4.02M Hold
50,000
– – 0.3% 89
2019
Q2 		$3.63M Hold
50,000
– – 0.09% 216
2019
Q1 		$4.67M Buy
+50,000
New +$4.18M 0.14% 190

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ALNY Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2019, closing a stake of 19,325 shares — an estimated $1.55M sold.

Arrowgrass Capital Partners (US) first reported a position in ALNY in Q1 2019 and held it in 3 quarters. The position peaked at $1.74M in Q2 2019. 316 funds tracked by Wall St. Rank hold ALNY as of Q4 2019.

  • Arrowgrass Capital Partners (US) reported no remaining Alnylam Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 19,325 Alnylam Pharmaceuticals shares in Q4 2019, an estimated $1.55M.
  • Arrowgrass Capital Partners (US) first reported a position in Alnylam Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Arrowgrass Capital Partners (US)'s Alnylam Pharmaceuticals position peaked at $1.74M in Q2 2019.
  • 316 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.